Dr. Eric Donnenfeld uses single-dose postoperative steroid — 4 insights

Eric Oliver - Print  |

Garden City, N.Y.-based Ophthalmic Consultants of Long Island's Eric Donnenfeld, MD, used EyePoint Pharmaceutical's single-dose postoperative steroid Dexycu in a cataract surgery patient.

What you should know:

1. Dexycu is an FDA-approved postoperative steroid designed to simplify the recovery process. Dexycu is single-dose steroid administered at the end of surgery that eliminates the need for a postoperative dosing regimen.

2. Dr. Donnenfeld performed the cataract surgery at Westbury, N.Y.-based Island Eye Surgicenter using Dexycu at its completion.

3. EyePoint is launching Dexycu through a phased rollout, starting with experienced cataract surgeons.

4. EyePoint will make Dexycu available to patients in need of financial assistance through its EyePoint Assist program.

More articles on leadership:
4 ways to reduce SSIs in ASCs
How to proactively tackle physician burnout: Acadia Healthcare CMO Dr. Michael Genovese weighs in
Arizona Medicaid program alerts 3,146 members of privacy breach: 3 details to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.